Top Markets
Coin of the day
Skye Bioscience, Inc. Skye Bioscience, Inc.

Skye Bioscience, Inc.

SKYE
Rang in Aktien #31353
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on... Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Aktienkurs
$0.4018
Marktkapitalisierung
$14.12M
Veränderung (1 Tag)
-3.20%
Veränderung (1 Jahr)
-88.15%
Land
US
Handel Skye Bioscience, Inc. (SKYE)

Kategorie

Dividendenrendite-Verlauf für Skye Bioscience, Inc. (SKYE)
Dividendenrendite (TTM) von Skye Bioscience, Inc. (Aktienkürzel: SKYE) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Skye Bioscience, Inc. (SKYE) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.48%
BE